The role of animal models in influenza vaccine research

Catherine J. Luke and Kanta Subbarao

*Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Abstract

A major challenge for research on influenza vaccines is the selection of an appropriate animal model that accurately reflects the disease and the protective immune response to influenza infection in humans. Vaccines for seasonal influenza have been available for decades and there is a wealth of data available on the immune response to these vaccines in humans, with well-established correlates of protection for inactivated influenza virus vaccines. Many of the seminal studies on vaccines for epidemic influenza were conducted in human subjects. Studies in humans are performed less frequently now than they were in the past. Therefore, as the quest for improved influenza vaccines continues, it is important to consider the use of animal models for the evaluation of influenza vaccines, and a major challenge for research on influenza vaccines is the selection of an appropriate animal model that accurately reflects the disease and the protective immune response to influenza infection in humans.

The emergence of highly pathogenic H5N1 avian influenza (AI) viruses and the threat of a pandemic caused by AI viruses of this or another subtype has resulted in a resurgence of interest in influenza vaccine research. The development of vaccines for pandemic influenza presents a unique set of obstacles, not the least of which is that the demonstration of efficacy in humans is not possible. Since the correlates of protection from pandemic influenza are not known, we rely on extrapolation of lessons from seasonal influenza vaccines and on data from the evaluation of pandemic influenza vaccines in animal models to guide our decisions on vaccines for use in humans. The features and contributions of commonly used animal models for influenza vaccine research are discussed.

Influenza viruses

Influenza is a negative-sense, single-stranded RNA virus belonging to the family *Orthomyxoviridae*. *Orthomyxoviridae* consist of four genera: influenza A, influenza B, influenza C and Thogoto viruses. The proteins of influenza A viruses are encoded by genes on eight RNA segments. Influenza A viruses are widely distributed in nature and can infect a wide variety of birds
and mammals, including humans. Influenza A virus subtypes are classified on the basis of the antigenicity of their surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA) [1, 2] into 16 HA subtypes and 9 NA subtypes, and all of these subtypes have been found to infect birds [2, 3]. Waterfowl and shorebirds are the natural reservoirs of AI viruses.

In their natural hosts, most AI infections are not associated with clinical disease, and the viruses are generally thought to be in evolutionary stasis [4]. In the human population, relatively few subtypes of influenza A viruses have caused sustained outbreaks of disease; viruses bearing H1, H2 and H3 HA and N1 and N2 NA genes have circulated in the human population during the 20th century. H1N1 viruses appeared in 1918 and circulated until 1957, when they were replaced by H2N2 viruses. These in turn were replaced in 1968 by H3N2 viruses, which continue to circulate at the present time. In 1977, H1N1 viruses reappeared and have continued to co-circulate with the H3N2 viruses. Influenza A and B viruses cause epidemics in humans each winter.

In addition to the seasonal influenza epidemics, the potential also exists for an influenza pandemic at any time. A pandemic occurs when an influenza strain with a novel HA subtype (with or without a novel NA subtype) appears and spreads in a susceptible human population. In the 20th century, influenza pandemics occurred in 1918, 1957 and 1968, and were associated with significant morbidity and mortality [5]. It is estimated that, in the United States alone, the next influenza pandemic could cause 89,000–207,000 deaths, and 314,000–734,000 hospitalizations, and tens of millions of outpatient visits and illnesses [6]. AI viruses in their natural reservoir in waterfowl and shorebirds are the source from which novel HA and NA subtypes are introduced into the human population. A novel AI HA and/or NA can be introduced into the human population by direct spread from either wild birds or domestic poultry, as was seen when an H5N1 AI virus infected humans in 1997 [7]. Alternatively, human and avian influenza viruses can reassort, generating virus that can efficiently spread in humans, as happened in the case of the 1957 H2N2 and 1968 H3N2 pandemic viruses [8].

Influenza A viruses also infect and cause disease in a wide variety of mammalian species, including swine, horses, ferrets, mink, dogs, seals and whales. The currently circulating highly pathogenic AI H5N1 viruses that emerged in Asia in 2003 can also infect and cause lethal infection in felids, including tigers, leopards and domestic cats [9, 10].

Although several animal species are infected with influenza A viruses naturally and experimentally, an ideal animal model for studying infection and immunity to human influenza has not been identified. Several animal species are permissive to infection with influenza A and B viruses to varying degrees and some exhibit clinical signs of illness and pathological changes in the respiratory tract that are similar to those seen in human influenza. In this chapter, we discuss the main features of the animal models used for
evaluation of influenza vaccines, their advantages and disadvantages, and their contribution to research on vaccines against influenza in humans. We also discuss the role of animal models in the development of vaccines against pandemic influenza. Veterinary vaccines for swine, equine, avian and canine influenza can be evaluated in their natural hosts and are not be discussed.

**Influenza vaccines**

Vaccines have been available for epidemic or ‘seasonal’ influenza since the 1940s. Inactivated influenza virus vaccines are largely the same now as they were when first developed. They are still generally produced in embryonated hen’s eggs. There has been much recent investment in the development of cell-based influenza vaccines, of which at least two are licensed in Europe and several others are in development in Europe and the United States. In 2003, live attenuated influenza vaccines were licensed in the United States for annual use in healthy individuals between 5 and 49 years of age.

A serum hemagglutination inhibiting (HAI) antibody titer of 1:32 or 1:40 or greater is associated with protection from seasonal influenza [11–13], and this is used as a measure to predict the protective efficacy of seasonal inactivated influenza virus vaccines. The correlates of protection for live attenuated vaccines are less clear-cut. These vaccines elicit systemic and mucosal immune responses and mucosal antibody in the respiratory tract is believed to play a major role in protection afforded by these vaccines [14–16].

Antigenic drift describes the gradual change in antigenicity of an influenza virus that allows the virus to escape neutralization by antibodies induced by infection or immunization with previously circulating strains. Antigenic drift results from point mutations in and around antibody-combining sites in the HA and NA proteins. Influenza virus vaccines are unusual in that one or more of the components of the trivalent vaccine formulation may have to be changed annually to keep pace with antigenic drift of the virus but as long as the licensed manufacturing process is used, the change in composition of the vaccine is considered a strain change and it is not treated as a new vaccine. Approval of seasonal influenza vaccines for use in humans requires limited testing in animals, and an evaluation of immunogenicity in humans is required in Europe but not in the United States.

In recent years, a resurgence of interest in improvement of seasonal influenza vaccines, and the looming threat of a possible influenza pandemic have spurred efforts to develop vaccines that could thwart the spread of an emerging pandemic virus. Extensive pre-clinical characterization of these new vaccines in animals will be necessary. Many researchers are engaged in efforts to develop ‘universal’ influenza vaccines that will protect against both epidemic and pandemic strains by targeting the more conserved antigens of the virus, such as nucleoprotein (NP) or matrix protein (M), thus
eliminating the need for constant updating of the composition of the annual seasonal influenza vaccine. The immune responses to candidate universal vaccines are entirely different from those elicited by the currently licensed seasonal inactivated influenza virus vaccines, where protective immunity is based mainly on neutralizing antibodies produced against the HA protein. Animal models are needed in which different types of immune responses can be evaluated.

One of the major challenges in the development of pandemic influenza vaccines is that correlates of protection from AI viruses of pandemic potential are not known. Efficacy of these novel influenza viruses cannot be established in humans, so assessment of efficacy is based on information gleaned from challenge studies in animals.

**Animal models for influenza**

Despite the diversity of mammalian species infected by influenza viruses in nature, only a few species are amenable to study in the laboratory. Tables 1–3 and the following sections summarize the features of the most commonly used small animal models for the study of influenza, and their respective utilities in the evaluation of influenza vaccines are summarized in Table 4. Commonly used laboratory animal species may not be fully permissive for infection with wild-type, non-adapted isolates of influenza viruses, and can vary in susceptibility to infection by specific virus strains and subtypes. Other variables that can influence the outcome of infection are the use of anesthesia, route of virus administration and the volume of inoculum.

**Rodent models**

Rodent models of infectious diseases are attractive for a number of scientific and practical reasons. They are small and relatively inexpensive to purchase and house. Many inbred strains are available and a battery of immunological reagents are available for some species.

**Mice**

Mice have been used for influenza vaccine research from the earliest days of the study of influenza virus biology. Shortly after the first human influenza virus was isolated from ferrets in 1933 by Wilson Smith and colleagues at the National Institute for Medical Research in London [17], it was discovered that human influenza viruses would cause disease in mice only if they were first adapted to the species by serial passages in the lungs [18]. This was sub-
sequently found to be true of all human influenza virus isolates. One of the most commonly used human influenza viruses in mouse studies is influenza A/Puerto Rico/8/34 (PR8), an H1N1 virus with a complex passage history, including several passages in ferrets, and hundreds of passages in eggs and mice (C.B. Smith, CDC, Atlanta, GA, personal communication). This virus is well adapted to mice and causes a lethal infection. The need for adaptation through serial passage of human influenza viruses is one of the major drawbacks of using mice in influenza research, because many mutations can arise during adaptation to the murine host [19–22] that can alter their replication kinetics, and can result in the ability of the virus to escape innate immune responses [23].

Influenza viruses that cause disease and are lethal for mice provide a useful endpoint for vaccine efficacy studies. Depending on the strain of virus used, mice may become lethargic, anorexic, develop ruffled fur, and may also exhibit neurological symptoms of infection, in addition to weight loss, which is often the primary objective measure of the severity of infection. Body temperature is not a useful measurement in mice because hypothermia can occur following infection with mouse-adapted viruses. Irrespective of whether an influenza virus induces morbidity or mortality in mice, the level of replication of influenza viruses in the lungs is the most informative endpoint for efficacy studies in mice, since even a modest reduction in titer of infectious virus in the lungs can be associated with survival from lethal infection [24, 25]. Mice immunized with influenza viruses or vaccines develop serum HAI and neutralizing antibodies, the titers of which correlate with protection from subsequent challenge. Studies by Virelizier [26] demonstrated that antibody alone could protect against influenza infection in mice. Passive transfer of immune serum to naive mice reduced replication of virus in the lungs, and protected the recipient mice from lethal influenza pneumonitis but did not prevent tracheitis or replication of virus in the upper respiratory tract [27]. The observation that passively transferred serum antibodies can reduce pulmonary virus replication but not viral replication in the upper respiratory tract is not unique to influenza A. Similar observations have been reported in influenza C virus [28], respiratory syncytial virus (RSV) [29] and severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infection [30]. When measuring the amount of virus in various tissues in cases where high levels of serum antibody are present, for example, when vaccines are administered with adjuvant, the presence of virus should be measured by quantitative molecular methods, to rule out the possibility of ex vivo neutralization by serum antibody during tissue preparation. Such ex vivo neutralization accounted for a reduction in detectable virus of up to 300-fold in the lungs of mice that had undergone passive transfer of immune serum against SARS-CoV [30]. The use of nasal and bronchiolar wash samples instead of tissue homogenates for viral quantitation was also employed as a solution to this issue [28].
Table 1. The use of the mouse model for the evaluation of vaccines against influenza.

| Influenza virus subtypes tested | Findings | Refs. |
|--------------------------------|----------|-------|
| 1. Human influenza H1N1, H3N2, H2N2 | - Human influenza virus isolates require adaptation to cause illness (lethality) in mice.  
- Infection under anesthesia results in viral pneumonia.  
- Clinical signs include ruffled fur, hunching, labored breathing, unsteady gait, hypothermia and weight loss.  
- Inflammation is observed in the respiratory tract | [18, 31, 32, 155] |
| 2. Reconstructed 1918 H1N1 pandemic virus | - Causes illness in mice and replicates efficiently in the respiratory tract without prior adaptation.  
- Up to 13% loss of body weight is observed.  
- Lethal to mice with an MDT of 4.5 days.  
- No extrapulmonary spread observed.  
- Necrotizing bronchitis and bronchiolitis, and moderate to severe peribronchial and alveolar edema present. | [131] |
| 3. HPAI H5N1 | - Most isolates cause severe illness and death without prior adaptation.  
- Replicate efficiently in the respiratory tract without prior adaptation.  
- Cause significant weight loss.  
- Most isolates are lethal in mice with a MDT of 6–8 days.  
- Some isolates are detected in extrapulmonary sites including the brain.  
- Variable virulence in mice is observed with isolates from Hong Kong from 1997, and 2003–2004, and viruses isolated from Europe and South America. | [100–104, 126, 133] |
| 4. H7 | - HP and LP isolates replicate efficiently in respiratory tract of mice without prior adaptation, with some viruses causing weight loss and death.  
- Extrapulmonary spread to the brain and spleen observed following intranasal infection with some isolates.  
- Histopathological observations following intranasal infections with human isolates include necrosis and inflammation throughout the respiratory tract, but no lesions in the brain, heart, spleen, liver or kidneys.  
- Histopathological lesions are observed following intranasal infection with HP avian isolates. | [114–117] |
| 5. H9N2 | - Replicate efficiently in lungs of mice without prior adaptation.  
- Conflicting reports of lethality in mice.  
- Adaptation by passage in mouse lungs results in increased virulence.  
- Replication in brain reported following intranasal infection with non-adapted and mouse-adapted viruses. | [121, 125–130, 156, 157] |
| 6. H6N1 | - A/teal/W312/HK/97 (H6N1) replicates efficiently without prior adaptation and is lethal for mice when administered at high titers.  
- Significant weight loss (average 24%) is observed in infected mice.  
- Adaptation to mouse results in increased virulence and spread to brain. | [125] |

MDT, mean time to death; HPAI, highly pathogenic avian influenza; HP, highly pathogenic; LP, low pathogenicity
The role of animal models in influenza vaccine research

Table 2. The use of the ferret model for the evaluation of vaccines against influenza.

| Influenza virus subtypes tested | Findings | Refs. |
|---------------------------------|----------|-------|
| 1. Human influenza H1N1, H3N2, H2N2 viruses | - Efficient replication of non-adapted isolates in respiratory tract.  
- Isolated report of the presence of an H3N2 human influenza virus in the brain.  
- Signs of illness include fever, sneezing, rhinorrhea, and weight loss.  
- Mild inflammatory changes are observed upon histopathological examination of lungs of infected animals. | [17, 132, 158, 159] |
| 2. Reconstructed 1918 H1N1 pandemic virus | - Replication to high titers in respiratory tract.  
- Severe disease observed including lethargy, anorexia, severe weight loss and high fever.  
- Infection is lethal in 2/3 of inoculated animals; death occurs by day 11.  
- Virus is not detected in brain or heart.  
- Necrotizing bronchiolitis, and moderate to severe alveolitis with edema observed upon histopathological examination. | [141] |
| 3. HPAI H5N1 | - Efficient replication in respiratory tract and evidence of extrapulmonary spread to brain, spleen and intestines.  
- Most isolates cause severe disease, including fever, rhinitis, sneezing, severe lethargy, hind limb paresis and diarrhea.  
- Many isolates cause lethal infection in ferrets.  
- Histopathological observations include inflammatory changes in the lungs (bronchiolitis, bronchitis, interstitial pneumonia) and inflammation in the brain. | [104, 132, 134] |
| 4. AI subtypes H1N1, H2N1, H6N2, H2N2, H2N3, H3N2, H10N7, H3N6, H7N7, seal H7N7 isolate | - Efficient replication in the upper respiratory tract.  
- No signs of illness with any of these isolates. | [140] |

AI, avian influenza

The level of anesthesia can influence the outcome of influenza infection in mice. Mice infected under anesthesia develop pneumonia, while infection is limited to the upper respiratory tract when awake mice are infected [31, 32]. Volume of inoculum administered intranasally also influences the extent to which virus is distributed in the respiratory tract [32]. Immunologically, the lack of a functional Mx gene in standard laboratory strains of mice presents a disadvantage in using this model for studies in which the innate immune response to infection is important [33, 34]. However, the ready availability of mice, their relatively low cost, and the variety of genetic backgrounds and targeted genetic defects, and the immunological reagents available still make the mouse an attractive and heavily utilized animal model for studies of influenza.
Table 3. The use of the hamster model for the evaluation of vaccines against influenza.

| Influenza virus subtypes tested | Findings                                                                 | Refs.       |
|--------------------------------|--------------------------------------------------------------------------|-------------|
| 1. Human influenza H3N2        | - Non-adapted isolates replicate in the upper and lower respiratory tract. | [35–37, 146]|
|                                | - No clinical signs of infection are observed.                           |             |
| 2. HPAI H5N1                   | - Non-adapted A/HK/483/97 (H5N1) resulted in lethal infection with deaths of all inoculated animals by day 6 post inoculation. | [146] |
|                                | - Virus is detectable in the lungs and brain.                           |             |
| 3. H9N2                        | - Non-adapted A/HK/1073/99 (H9N2) replicates to high titers in the lungs but is not detected in the brain. | [146] |
|                                | - Infection is not lethal.                                              |             |
| 4. H9N5                        | - Non-adapted A/dk/HK/702/79 (H9N5) replicates efficiently in the lungs. | [146] |
|                                | - Infection is not lethal.                                              |             |

Hamsters

Influenza virus infection of hamsters with non-adapted human influenza viruses does not result in clinical disease, but the virus replicates to high titers in the nasal turbinates and lungs following intranasal infection [35–37]. As with mice, the hamster represents a readily available small animal model that can be used for pre-clinical evaluation of candidate vaccines, but it has not been used as extensively as mice have been for studies of inactivated influenza virus vaccines. The body temperature of Golden Syrian hamsters is about 39 °C, while that of mice is 37 °C. Thus, hamsters have been used for the evaluation of live attenuated temperature-sensitive vaccines with shut-off temperatures of ≥38 °C [38].

Guinea pigs

Guinea pigs can be infected with non-adapted human influenza viruses, although the amount of virus needed to infect guinea pigs is about ten times more than the amount of virus needed to infect hamsters or ferrets [39]. Infection of guinea pigs with A/England/42/72 (H3N2) did not result in febrile illness or other clinical signs of influenza infection. Virus was isolated from nasal washes of animals infected with influenza A/England/42/72 (H3N2), A/Hong Kong/1/1968 (H3N2) or A/FM/1/47 (H1N1), but titers shed in the nasal secretions were not as high as those observed following experimental infection of ferrets. Infection of guinea pigs with influenza A/HK/1/68 (H3N2) virus resulted in pneumonia, which developed slowly and was reversible. This model was used to study the
Table 4. Comparison of the utility of commonly used animal models in the evaluation of influenza vaccines.

| Species       | Utility in vaccine evaluation                                                                 |
|---------------|---------------------------------------------------------------------------------------------|
| Mouse         | - Determination of level of replication of live attenuated vaccine candidates in comparison to wild-type viruses. |
|               | - Evaluation of antibody responses to vaccination by HAI assay, Nt Ab assay, ELISA.         |
|               | - Evaluation of cellular immune responses to vaccination.                                   |
|               | - Evaluation of vaccine efficacy and effects of adjuvants.                                  |
|               | - General safety test for manufactured candidate vaccines.                                  |
| Ferret        | - Determination of level of replication of live attenuated vaccine candidates in comparison to wild-type viruses. |
|               | - Evaluation of antibody responses to vaccination by HAI assay, Nt Ab assay, ELISA.         |
|               | - Limited evaluation of cellular immune responses to vaccination.                          |
|               | - Evaluation of vaccine efficacy and effects of adjuvants.                                  |
|               | - Toxicology studies.                                                                     |
| Hamster       | - Determination of level of replication of temperature-sensitive live attenuated vaccine candidates. |
|               | - Evaluation of vaccine immunogenicity by HAI assay, Nt Ab assay and ELISA.                |
|               | - Evaluation of vaccine efficacy.                                                          |

HAI: hemagglutination inhibition; NtAb: neutralizing antibody; ELISA: enzyme-linked immunosorbent assay.

effects of environmental pollutants or drugs on the respiratory tract [40]. Lowen and colleagues [41] reported that Hartley strain guinea pigs are highly susceptible to non-adapted influenza A/Panama/2007/99 (H3N2) virus. Intranasal infection resulted in virus replication in the nose and lungs, with higher titers of virus recovered from the lungs. Virus was recovered from the upper respiratory tract for up to 9 days post inoculation, whereas shedding declined to undetectable levels in the lungs by day 5. Virus replication was not associated with any effects on body temperature or weight of the animals, and no other clinical signs of illness were observed.

**Rats**

Common laboratory strains of rat are described as ‘semi-permissive’ for influenza infection, and infant rats are of some utility in the evaluation of live attenuated influenza vaccines, but they have not been used extensively to study influenza infection [42–44].

The cotton rat (*Sigmodon hispidus*) has been used in the laboratory as a model for several infectious diseases (reviewed in [45]). In particular, the cotton rat model was used extensively for the development of therapeutic
antibody treatments for RSV and has provided much useful information for vaccine development against this pathogen. Sadowski and co-workers reported that intranasal administration of human influenza virus to lightly anesthetized, outbred young adult cotton rats resulted in virus replication in the respiratory tract, production of pulmonary lesions and a strong immune response [46]. In recent years, there has been some renewed interest in the cotton rat as a laboratory animal model for human influenza virus infection. Species-specific reagents that permit more detailed analysis of viral pathogenesis and immune responses in this species have been developed [45] and inbred cotton rats are now available. The advantages of this model include the fact that cotton rats can be infected by non-adapted human influenza viruses, inbred animals are available, the virus replicates in the upper and lower respiratory tract, some clinical parameters can be measured, and virus infection results in histopathological changes in the lungs that are similar to those seen in the natural infection of humans [47]. To date only a limited number of human influenza viruses have been evaluated in cotton rats.

**Ferrets**

Ferrets are exquisitely susceptible to infection with human influenza viruses. The initial isolation of a human influenza virus by Smith and colleagues involved ferrets [17]. The ferret model of influenza has remained the same since this fortuitous discovery, and, in the opinion of many researchers, the ferret remains the ideal small animal model for influenza research. Ferrets can be infected with non-adapted human influenza virus isolates. Influenza virus infection in ferrets is primarily an upper respiratory tract infection, and infected ferrets exhibit clinical signs of infection similar to those seen in human influenza including fever, rhinitis and sneezing. The disadvantages of the ferret as a model for studying influenza vaccines include expense, special housing requirements, a limited number of suppliers, the difficulty in obtaining animals that are seronegative for influenza virus, their exquisite sensitivity to other respiratory pathogens and ease of acquiring infection from their handlers, and the lack of species-specific reagents, although this last point does not present an obstacle for the evaluation of HAI and neutralizing antibody responses. In addition, the high body temperature of ferrets (average temperature of 38.8°C) may limit their utility in the evaluation temperature-sensitive live attenuated influenza vaccines.

**Non-human primates**

Non-human primates have not been used extensively for influenza vaccine research. From a practical standpoint, these animals are expensive and they
have not proven to be the best model for the study of vaccines for influenza. Old and New World species of monkeys have been evaluated as models of human influenza infection. It was determined early in the days of the study of influenza virus biology that non-human primate species were not as susceptible to human influenza viruses as their human relatives. Burnet reported in 1941 [48] that clinical signs of infection were only apparent in cynomolagus macaques when they were infected via the intratracheal route as opposed to intranasally. Interestingly, mortality was observed in animals inoculated with the ‘W.S. Egg’ strain, but the details of the derivation of this strain beyond the original isolation from Wilson Smith are not clear. Burnet reported that pathological changes consistent with those seen in human influenza infection were observed in the lungs of infected monkeys. The observation that intratracheal infection of monkeys might be required to achieve clinical signs of infection was supported by studies conducted by Saslaw and colleagues [49] in Rhesus macaques. Intratracheal infection of Rhesus macaques with a lung filtrate from mice infected with mouse-adapted A/PR/8/34 (H1N1) resulted in clinical signs of illness on day 2 post infection (p.i.), that resolved by day 4 p.i., whereas no signs of illness were apparent in monkeys inoculated with the same virus preparation intranasally, although both groups of animals showed hematological and serological evidence of infection.

Cynomolagus macaques were explored as a model for evaluation of the immunogenicity and efficacy of an immunostimulating complex (ISCOM) influenza vaccine by Rimmelzwaan and colleagues [50]. Cynomolgus macaques inoculated intratracheally with the human influenza A/Netherlands/18/94 (H3N2) virus did not develop clinical signs of illness but virus was recovered from lung lavage, nasal swabs and pharyngeal swab samples. Histopathological examinations were not performed.

Pigtailed macaques (Macaca nemestrina) were infected with a recombinant human influenza A/Texas/91 (H1N1) virus following virus administration via the trachea, tonsils and conjunctiva [51]. The animals exhibited clinical signs of infection, including loss of appetite, weight loss, nasal discharge and moderate fever, and histopathological observations that were consistent with progressive pneumonia. Virus was recovered from lung tissue at day 4 but not at day 7 p.i.

New World monkeys – including squirrel and cebus monkeys – have been evaluated as models for influenza vaccine studies. Murphy et al. [52] demonstrated that adult squirrel monkeys could be infected with intratracheally administered human influenza viruses. Mild illness that manifested as afebrile coryza was seen and, although radiographic evidence of pneumonia was not observed, the animals shed virus from the respiratory tract. Further studies evaluated the ability of AI viruses to replicate and cause illness in this species [53]. Different viruses caused varying degrees of clinical illness; some influenza viruses were completely attenuated in squirrel monkeys, while others replicated efficiently and caused clinical signs of similar sever-
ility to that seen in human H3N2 influenza infection. Squirrel monkeys were employed to evaluate the level of attenuation of avian/human influenza virus reassortants in a study comparing the replication of reassortants with findings in chimpanzees and human volunteers [54]; the findings in squirrel monkeys were not predictive of the level of attenuation of the reassortant viruses in humans.

_Cebus apella_ and _Cebus albifrons_ monkeys were evaluated as models for influenza infection by Grizzard et al. [55]. The monkeys were inoculated either intranasally or intratracheally with two human influenza A viruses: A/Victoria/75 (H3N2) and A/New Jersey/76 (H1N1). All animals that received the A/Victoria/75 (H3N2) strain developed clinical signs of illness, and had evidence of infection by either virus shedding or serology. Radiographic evidence of pulmonary disease was only seen in animals inoculated intratracheally with A/Victoria/75 (H3N2). Eight of ten animals inoculated intratracheally with the A/New Jersey/76 (H1N1) virus had mild upper respiratory tract illness, but only one of ten animals shed virus. However, all of these animals seroconverted. Histopathological evidence of inflammation in the lungs and trachea was seen in animals inoculated intratracheally with either strain, although the lesions in the animals that received A/Victoria/75 (H3N2) were more severe.

Chimpanzees are considered to be a valuable animal model to study infections of humans because of their close evolutionary relationship with the human species. However, the use of chimpanzees as animal models in research is logistically difficult. They are extremely expensive animals that require long-term care and stringent isolation since they are susceptible to several human pathogens. Chimpanzees have been used for some studies with influenza [54,56,57]. Influenza A and B viruses replicated to high titer in seronegative chimpanzees, but viral replication was not associated with illness. Advantages of studying influenza in this species include the fact that chimpanzees have the same body temperature as humans, the lower respiratory tract can be repeatedly sampled safely, they display permissiveness for vectored vaccines similar to humans (for example, vaccinia-based vaccines) and they are evolutionarily close to humans and this may mean that similar host-range restrictions for replication of viruses may be present, which could facilitate selection of live attenuated candidate vaccines for testing in humans.

There is renewed interest in the use of non-human primates for evaluation of vaccines for pandemic influenza (see *Vaccines for pandemic influenza* below).

**Animal models in influenza vaccine research**

The three general areas of vaccine research and development in which animal models are utilized are for the evaluation of vaccine safety, immunoge-
nicity and efficacy. The following sections describe the use of animal models in each of these aspects of the pre-clinical evaluation of influenza vaccines.

Safety

Early in the days of clinical testing of live attenuated vaccines against seasonal influenza, it was recognized that an animal model that could predict the attenuation of these vaccines would allow progression to immunogenicity and efficacy testing to occur more rapidly. Ideally, systematic comparisons of the behavior of attenuated virus vaccine candidates in animal models and in humans are needed to achieve this end. Researchers began to address this question in the late 1970s and early 1980s, and the infant rat was extensively investigated as a model to predict the restriction of replication of live attenuated influenza vaccines in humans [42–44]. In general, attenuation in the infant rat model correlated with attenuation in humans, although there were exceptions. Other species evaluated for this purpose include mice, hamsters, ferrets and chimpanzees.

Although vaccine safety can only be fully assessed when a vaccine is administered to human subjects, regulatory authorities usually recommend standard tests for pre-clinical evaluation of the safety of new vaccine candidates. The primary safety concern for inactivated influenza virus vaccines is reactogenicity, and for live attenuated influenza vaccines, it is the level of attenuation and genetic stability. Standard toxicology tests on new vaccine candidates are often performed in rabbits, although current WHO guidelines for nonclinical evaluation of vaccines recommend that toxicology studies be performed in an animal species that most closely reflects the immune response to the vaccine in humans, or is ‘sensitive to the biological effects of the vaccine’, using the dose and route of administration to be studied in clinical trials [58]. The design and results of such studies should be reviewed with special attention to experimental details such as the route of administration, volume and quantity of virus in the inoculum, and whether or not anesthesia was used, particularly for live attenuated vaccines, because each of these factors can influence the outcome. Toxicity following administration of very high doses of live influenza virus to animals via a variety of routes has been reported in the literature. For example, administration of 10^9 EID₅₀ of influenza virus administered intranasally resulted in complete pulmonary consolidation and death in mice, and this pathology occurred despite restricted replication of virus in lung tissue [59]. Henle and Henle [60] reported inflammation in the gut, damage to the liver and spleen, and death in mice given high doses of influenza virus intraperitoneally. Similar findings were observed in rats, rabbits and guinea pigs. Lung inflammation was observed in ferrets administered high titer live attenuated influenza viruses intranasally [60a] and systemic signs of illness were reported in human volunteers who received attenuated influenza viruses at doses that exceeded 10^7 TCID₅₀
In these studies, signs of clinical illness, including fever and other systemic signs, appeared within 48 h of administration of the virus, which is more rapid in general than the appearance of symptoms associated with productive influenza virus infection. The systemic symptoms did not correlate with the titer of virus shed in respiratory secretions, or with the occurrence of respiratory symptoms. The occurrence of systemic illness in humans following administration of high doses of influenza virus in the absence of high levels of virus replication may be explained by the innate immune response to an abortive infection of epithelial cells.

The current procedures for marketing approval of vaccines for seasonal influenza do not involve extensive safety testing in animals. In the US, a standard general safety test, which is designed to detect extraneous toxic components in the vaccine preparation, is usually performed with the final drug product in mice and guinea pigs [64]. This test is performed for both inactivated and live attenuated virus vaccines. For inactivated influenza virus vaccines, vaccine can be administered via either the subcutaneous or intraperitoneal routes for the guinea pig test, whereas only the intraperitoneal route can be used for other types of vaccine. The vaccine formulation must also be certified to be free of endotoxin.

New vaccine candidates or novel preparations (including vaccines prepared by currently licensed methodologies that are now formulated with adjuvant), require extensive pre-clinical safety testing. In addition to tests such as repeat dose toxicology testing and general safety testing, some tests would be appropriate for the specific type of vaccine, e.g., demonstration of attenuation of live attenuated vaccines compared to the wild-type parent virus in more than one animal species [16, 65, 66], and biodistribution studies for plasmid-based vaccines [67–71].

Ferrets have been used to assess the attenuation of cold-adapted live attenuated vaccines for influenza [72]. These studies showed that cold-adapted 6-2 reassortant vaccine viruses generated from human influenza viruses failed to replicate in the lower respiratory tract of ferrets. Since ferrets are a good model for influenza infection in humans, they can also be used in toxicological studies of influenza vaccines.

The attenuation phenotype of several live attenuated influenza vaccine candidates was evaluated using the hamster model [35, 37]. For the small number of temperature-sensitive, cold-adapted reassortant influenza viruses tested in hamsters and later in humans, there was generally a correlation between the level of replication in hamsters and humans. However, in studies with AI/human influenza virus reassortants, the findings in hamsters did not accurately predict the level of attenuation of the viruses for humans [73]. Such data are important because they demonstrate that the genetic determinants for attenuation of influenza viruses are different in different species.

Non-human primate species have not been used extensively in studies of the safety of influenza vaccines. Chimpanzees were used in several studies to evaluate the level of attenuation and safety of candidate live attenuated
vaccines [73]. Regulatory authorities in Europe require neurovirulence testing of live attenuated influenza vaccines and inactivated vaccines that are to be administered intranasally [74]. Since influenza viruses are not central nervous system pathogens in humans, the wisdom of such requirements, which were designed to determine the safety of live attenuated vaccines for truly neurotropic viruses such as poliovirus, can be questioned. The neonatal rat was recently proposed as a model in which to study neurovirulence of intranasally administered influenza vaccines [75], and a few influenza strains were evaluated in this model. Some viruses replicated in the brain following intranasal administration, but pronounced lesions or dramatic behavioral changes were not demonstrated in infected animals.

**Immunogenicity**

The vast majority of studies conducted in animals in influenza vaccine research are those that evaluate the immune response to candidate vaccines. Although it is clear that the immune responses to vaccines in animals are not often identical to and may not be directly predictive of those seen in humans, the first step in the proof-of-principle of a new vaccine is to establish the immunogenicity of a vaccine candidate in animals before proceeding to clinical evaluation. The immune responses measured in the animal model should be relevant to the desired response in humans. Such studies may provide useful information regarding regimen and routes of vaccination to guide the design of clinical trials.

**Strain-specific immunity directed against the HA**

It is well established that the primary correlate of protection for inactivated whole-virus or subunit influenza vaccines administered parenterally is serum antibody directed against the HA protein. Most studies that are conducted to evaluate immune responses to influenza vaccines are conducted in mice and ferrets. Measurement of antibody responses in animal models is very straightforward, since HAI and neutralizing antibody assays do not require species-specific reagents. Limited studies have been conducted to evaluate the guinea pig as a model to study immunity to influenza virus. Phair and colleagues [39] demonstrated that infection of guinea pigs with unadapted human influenza viruses resulted in resistance to challenge with homologous virus, and that passive transfer of hyperimmune serum to naive guinea pigs also conferred protection against infection. However, the levels of HAI antibody detected in serum following infection were lower than those observed in ferrets or hamsters, and infected guinea pigs did not produce detectable levels of local antibody in nasal secretions. In addition, high levels of nonspecific inhibitors of hemagglutination were present in guinea
pig sera, making measurement of specific HAI antibodies problematic [39]. Phair et al. did, however, demonstrate that guinea pigs exhibited a delayed-type hypersensitivity response to influenza infection that resembled that seen in humans, although this response did not appear to be involved in resistance to infection.

Humoral immune responses to the HA of human influenza viruses and vaccines have been studied extensively in ferrets. Early studies determined that naive ferrets were not protected against influenza infection by vaccination with killed virus [76]. These observations were confirmed in later studies using formalin-inactivated vaccines [77]. However, killed vaccine administered with adjuvant to naive ferrets provided partial protection against infection [78]. Thus, immune responses in the ferret to vaccination with inactivated virus vaccines against human influenza viruses do not appear to be identical to those seen in humans, since humans do not generally require adjuvant to achieve protective levels of HAI antibodies. In contrast to the findings with inactivated influenza viruses, immunization with live influenza virus resulted in protection against subsequent challenge [77]. An explanation for this difference may be that in ferrets, influenza infection is primarily an upper respiratory tract infection, and adjuvant is required to elicit higher levels of serum antibody needed to restrict replication of virus in the upper respiratory tract. Several studies have demonstrated that higher levels of serum antibody are required to provide protection against respiratory viruses in the nose of animals than in the lungs [27–29].

**Heterosubtypic immunity**

In recent years, and particularly since the emergence of the highly pathogenic H5N1 viruses in Asia in 2003, and the challenges in developing H5N1 vaccines, there has been a resurgence of interest in heterosubtypic immunity – the ability of an immune response elicited by a particular influenza A virus to protect against an influenza A virus of a different subtype. Heterosubtypic immunity against influenza has been demonstrated in a number of studies in mice but the precise mechanism of this immunity is not clear [79–82]. Previously, it was thought that this phenomenon was mediated by cellular immune responses, but recent studies suggest that antibody is the primary mechanism of heterosubtypic immunity [82] and that the diversity of the antibody repertoire is important [83].

Heterosubtypic immunity has also been observed in ferrets [84, 85], although there was some debate as to the length of time that such immunity persists. McLaren and Potter [84] reported that it did not persist beyond 10 weeks after vaccination, but in another study, protection against infection with a heterosubtypic virus was observed 18 months following immunization [86]. In both cases, heterosubtypic immunity did not prevent infection but limited virus replication following challenge.
The role of animal models in influenza vaccine research

The utility of the cotton rat model to address the question of heterosubtypic immunity was explored [87]. The endpoints in this study were respiratory rate, virus replication in lungs and nasal tissues, and pulmonary histopathology. A statistically significant reduction in respiratory rate was seen following challenge with A/Wuhan/359/95 (H3N2) in cotton rats that had been immunized with either the homologous virus or with a virus of a different subtype, A/PR/8/34 (H1N1), 4 weeks earlier, compared to non-immunized animals. This reduction in respiratory rate correlated with a statistically significant reduction in virus titers in the lungs and nasal tissues in immunized animals. Cotton rats that were immunized with the heterosubtypic A/PR/8/34 (H1N1) virus had the same extent of alveolitis, interstitial pneumonia and airway debris as non-immune, infected animals, and, like the cotton rats that were immunized with homologous virus, they had more severe early peribronchiolitis than was observed in primary infection. This peribronchiolitis could be indicative of a memory response in the heterosubtypic immune animals. However, heterosubtypic immune cotton rats had less bronchiolar epithelial damage than those animals immunized with homologous virus.

The role of heterosubtypic immunity through prior exposure or vaccination in man, although inferred from retrospective analysis of data from influenza pandemics [88], is extremely complex and cannot be readily determined. Studies in young infants and children in which the effect of pre-existing immunity on replication and immunogenicity of heterosubtypic attenuated influenza viruses suggested that heterosubtypic immunity in humans is weak [89].

Immune responses to other influenza proteins

An approach that is being explored in the development of novel vaccines for influenza is that of universal influenza vaccines that target the conserved proteins of the virus – NP, M1 and M2. A number of modalities such as NP and M DNA vaccines [90–92], baculovirus-expressed recombinant M2 protein [93], M2 peptides [94] and recombinant M2 protein incorporated into hepatitis B core antigen [95–97] have been tested in mice, and prevent death, but not illness, following challenge with heterologous virus. In the case of candidate universal vaccines for influenza, new animal models and assays are needed in which antibody and cellular responses to viral antigens other than the HA and NA can be measured. Since the immune responses to these conserved antigens are not well characterized in humans, at present it is not clear whether these responses are accurately reflected in animal models. Undoubtedly more information will be obtained in this area in the future as candidate universal vaccines are evaluated in clinical trials.

There has also been recent interest in the role of immune responses to the NA component of seasonal vaccines in protection against related subtypes of influenza, including potential pandemic strains [98]. Antibodies to
the NA protein can modulate the severity of influenza illness [99] but the NA content of inactivated influenza virus vaccines is not standardized.

**Efficacy**

Animal models are also used to evaluate the efficacy of new candidate influenza vaccines. The most commonly used animal models for such studies are mice and ferrets. In mice and ferrets it has been established that antibody against the HA can prevent infection or ameliorate disease following challenge with influenza virus. Reduction in virus titer in the lower respiratory tract following challenge correlates with protection, so quantitative virology is the most relevant measure of vaccine efficacy for vaccines designed to generate antibody responses to the HA. Additional endpoints such as morbidity, mortality and pathological findings may provide supporting evidence of protection from infection and disease. Although demonstration of vaccine efficacy in an animal model is not an absolute requirement in pre-clinical evaluation of a vaccine candidate from a regulatory standpoint, it provides evidence that immune responses to the vaccine are biologically relevant.

**Vaccines for pandemic influenza**

The direct transmission of HPAI H5N1, H7N7 and low pathogenicity AI (LPAI) H9N2 viruses from birds to humans, associated in many cases with severe morbidity and mortality, has raised concerns about the emergence of a new pandemic virus and has prompted efforts to develop vaccines against AI viruses of pandemic potential. Evaluation and characterization of a suitable animal model for these other influenza virus subtypes is a critical step in the development of such vaccines.

**Animal models**

In the following section we describe the features of the animal models that have been developed to study AI viruses, and their contributions to the evaluation of pandemic vaccines.

**Mice**

Mice have been used in pre-clinical studies of inactivated and live attenuated pandemic influenza virus vaccines. Most reports in the literature that describe the characterization of replication, pathogenicity and the immune
response of AI viruses in mice focus on viruses of the H5, H7 and H9 subtypes.

H5N1 viruses and vaccines

Several studies demonstrated that the H5N1 viruses isolated from human cases in Hong Kong in 1997 cause disease and death in mice without prior adaptation [100–102]. The Hong Kong H5N1 viruses isolated from humans in 1997 varied in their ability to cause disease and death in BALB/c mice and generally fell into two distinct groups – those that were highly virulent, and those of low virulence for mice – and one virus (A/HK/156/97) was of intermediate virulence in two of the studies [101, 102], but Gao et al. [100] found this isolate to be one of the most highly virulent in this model. The 50% lethal dose of H5N1 viruses that were highly virulent for mice were 10–1000 times lower than those of low virulence, they replicated to titers up to 1000 times higher in the lungs of mice early in the course of infection, and they replicated in extrapulmonary sites including the brain. Viral antigen was observed by immunohistochemistry in the lungs of mice infected with A/HK/483/97 (H5N1), a highly virulent strain, and A/HK/486/97 (H5N1), a less virulent strain, and was associated with necrotic bronchi. Viral antigen was also observed in both glial cells and neurons in the brain of mice infected with the highly virulent influenza A/HK/483/97 (H5N1) virus, a finding also reported by Gao et al. [100]. In addition, Gao et al. reported the presence of viral antigen in the cardiac myofibers in mice infected with the highly virulent influenza A/HK/483/97 (H5N1) virus. The ability of the H5N1 viruses to replicate and cause disease and death in mice did not correlate with their ability to kill chickens [102], and the relevance of replication of these viruses in extrapulmonary sites in mice to the human disease is not clear, although a general correlation between the level of virulence in mice and the severity and outcome of disease in humans was observed with 11 of 15 viruses evaluated [101]. Dybing and colleagues [103] reported that infection of mice with highly pathogenic H5 AI viruses that were isolated from Scotland [influenza A/ck/Scotland/59 (H5N1)], Italy [influenza A/ck/Italy/1485-330/97 (H5N2)], Queretaro [influenza A/ck/Queretaro/7653-20/95 (H5N1)] and England [influenza A/ck/England/91 (H5N1)], caused little or no disease in BALB/c mice, HPAI H5N1 influenza viruses isolated from humans in Asia in 2004 caused weight loss, ruffled fur, listlessness and pronounced leukopenia, and were lethal in mice without prior adaptation, and replicated outside the respiratory tract [104]. In the same study, HPAI H5N1 viruses isolated from birds, and a single human isolate, were less virulent for mice.

Lu et al. [102] used the BALB/c mouse model to evaluate the immunogenicity and efficacy of a vaccine for H5N1 influenza based on an antigenically related non-pathogenic AI virus, A/duck/Singapore-Q/F119-3/97
(H5N3). They found that two doses of inactivated vaccine were required to elicit HAI antibody responses of a magnitude that would be protective in human influenza in the majority of vaccinated animals, and that the addition of alum adjuvant resulted in higher levels of HAI antibody and a greater seroconversion rate. These findings generally agreed with the observations made in humans when a similar vaccine was tested in clinical studies: two doses of vaccine were necessary to achieve acceptable levels of antibody, and the addition of adjuvant, in this case MF59 (instead of alum used in the studies in mice), increased the magnitude of the antibody response as well as the seroconversion rate [105–107]. Efficacy of this vaccine in mice was determined by measurement of the level of virus replication in the lungs and protection against lethal challenge with an H5N1 isolate that was highly virulent in mice.

The efficacy of several different H5N1 virus vaccines have been evaluated in mice and in all cases, the vaccines were immunogenic and protective in mice (reviewed in [108]). When tested in Phase I studies in humans, inactivated H5N1 virus vaccines were found to be suboptimally immunogenic, requiring high doses [109, 110] to elicit neutralizing and HAI antibody responses. Administration of whole virion vaccines and inactivated virus vaccines with adjuvant increased immunogenicity in mice, and in humans [109, 111]. It is unclear whether data obtained in mice with pandemic influenza vaccines are predictive of vaccine immunogenicity in humans since pre-clinical data for the specific vaccine formulations that have been tested in humans to date have not been reported.

Cold-adapted live attenuated vaccine candidates against H5N1 AI viruses have been developed, and were found to be immunogenic and to confer protection against challenge with homologous and heterologous wild-type viruses in mice [65, 112, 113]. Some of these vaccines are currently in clinical trials, and so the predictive value of the information gained from studies in mice cannot be fully assessed at this time.

H7 viruses and vaccines

Representative low pathogenicity and highly pathogenic H7 AI viruses from both the Eurasian and North American lineages replicated in mice without prior adaptation [114]. Highly pathogenic H7 viruses demonstrated extrapulmonary spread to the spleen and brain, as has been observed with HPAI H5N1 isolates, although H7 viruses were detected in the brain earlier in infection (day 1 p.i. for H7 and day 4 for H5). de Wit et al. [115] reported that intranasal infection of mice with the non-adapted HPAI A/Netherlands/219/2003 H7N7 virus, that was isolated from a fatal human case, resulted in severe illness indicated by weight loss, lethargy, ruffled fur, and lethality. The rate of loss in body weight was similar over a range of doses of virus between $3 \times 10^3$ and $3 \times 10^6$ EID$_{50}$. The virus was detected
in the spleen, liver, kidneys and brain, as well as in the lungs of mice. This model was used for the evaluation of the immunogenicity and efficacy of candidate H7 influenza vaccines [115]. A single dose of an ISCOM vaccine and two doses of a subunit vaccine failed to protect mice against lethal infection with the A/NL/219/2003 (H7N7) virus, with one exception. Mice vaccinated with two doses of 1 μg or 5 μg ISCOM vaccine exhibited a small temporary loss in body weight but otherwise appeared healthy after challenge. Vaccination with two doses of the ISCOM vaccine resulted in at least a 1000-fold reduction in virus replication in the lungs, and near-complete reduction of extrapulmonary replication of challenge virus. However, in all vaccinated mice, virus was still present in the lungs at high titers.

Munster et al. [116] reported that the human HPAI H7N7 viruses A/NL/219/2003 and A/NL/33/2003 both caused lethal infection in mice when administered intranasally at a high dose (dose not specified). At a dose of 5 × 10^2 TCID_{50}, influenza A/NL/219/2003 virus, which was isolated from a fatal human case, resulted in loss of body weight, ruffled fur, lethargy, and respiratory problems from day 2 p.i., and infected mice were euthanized on day 5 p.i., whereas mice infected intranasally with 5 × 10^2 TCID_{50} of influenza A/NL/33/2003 virus, isolated from a human with conjunctivitis in the same outbreak, no signs of illness or loss in body weight were observed up to day 7 p.i. The influenza A/NL/219/2003 virus replicated to a titer that was more than 1000-fold higher in the lungs of infected mice than influenza A/NL/33/2003 virus, and was isolated from the brain, spleen, liver and kidney of all infected animals. Influenza A/NL/33/2003 virus was isolated from the brain of only one out of three mice, and was not detected from the other organs examined. Histopathological findings for all mice infected with influenza A/NL/219/2003 virus included necrosis and inflammation throughout the respiratory tract that was pronounced in the trachea, and became progressively milder in the bronchi, bronchioles and alveoli. In contrast, lesions in the respiratory tract were only observed in one out of four mice infected with influenza A/NL/33/2003 virus, and were characterized as mild to moderate cell necrosis, with neutrophil infiltrates in the trachea, bronchi and bronchioles. Lesions were not observed upon histopathological examination of brain, heart, spleen, liver or kidneys of mice infected with either virus. Viral antigen expression was limited to the respiratory tract tissues in mice infected with either virus, but was more abundant in mice infected with influenza A/NL/219/2003 virus. Rigoni and colleagues [117] reported that HPAI H7N1 viruses isolated from chickens and ostriches could infect and replicate in mice without adaptation, and were associated with disease signs of varying severity. Bronchitis, tracheitis, alveolitis and brain lesions were observed in mice infected with three HPAI H7N1 influenza viruses. However, the influenza A/ostrich/2332/00 virus caused more severe lesions and spread more rapidly in the lungs and brain than the other two viruses (influenza A/ostrich/984/00 and influenza A/ck/5093/99) [117].
Low pathogenicity H7 viruses replicated to high titers in the upper and lower respiratory tract of mice, but were not lethal, even at high doses. Immunogenicity of these viruses was also evaluated in mice [114].

H9 viruses and vaccines

Human infections with H9N2 AI viruses were first reported in 1999 [118, 119], and, although the illness in the infected individuals was relatively mild, there is still concern over the pandemic potential of H9 viruses because viruses of this subtype are highly prevalent in birds [120–124]. The pathogenicity of human and avian H9 influenza viruses in mice has been studied by several laboratories, with a view to the establishment of an animal model that can be used to study strategies for prevention, including vaccines and antiviral drugs. Some H9 influenza viruses replicate in the respiratory tract of mice without prior adaptation [121, 125–127], but serial passage of the A/quail/Hong Kong/G1/97 (H9N2) virus in mice resulted in an increase in virulence and in extrapulmonary spread and lethality of this virus in intranasally infected mice [125, 126]. Data from different laboratories using the same H9N2 virus to infect mice are not consistent. Some of the factors that can influence the outcome of infection are anesthesia, dose, volume and route of virus administration and passage history. It is difficult to compare studies when complete information is not provided. For example, in studies reported by Lu et al. [127], the human influenza A/Hong Kong/1073/99 (H9N2) virus replicated efficiently in the lungs of mice but failed to cause death or signs of disease, significant weight loss or to spread to extrapulmonary sites. However, Leneva et al. [125] reported that infection of mice with this virus resulted in 40% mortality and significant weight loss in the surviving mice. In these discordant studies, mice were anesthetized with CO₂ [127] or with metofane [125], were infected by the same route using virus that had been propagated in embryonated eggs, at approximately the same dose (10⁶ EID₅₀), but inoculum volumes used were not stated in either study, so it is not clear why this virus was lethal in one study and not in the other. Similarly, lethal challenge of mice with the human influenza A/Hong Kong/1073/99 (H9N2) virus was reported as part of a study to determine the efficacy of an M2 liposome vaccine [128], although this virus did not cause disease or lethality in the hands of other investigators [127, 129, 130]. All laboratories delivered virus intranasally to anesthetized mice. However, in the study reported by Ernst et al. [128], mice were anesthetized intraperitoneally with ketamine/xylazine, whereas in the other two studies, inhalational anesthesia was used, which may result in a lighter state of anesthesia.

The mouse model was used to evaluate the level of attenuation and the protective efficacy of a cold-adapted live attenuated H9N2 vaccine candidate bearing the HA and NA from the influenza A/ckHK/G9/97 (H9N2) virus and the internal protein genes from the influenza A/Ann Arbor/6/60
cold-adapted virus [129]. The H9N2 live attenuated vaccine was restricted in replication and protected mice from challenge with homologous and heterologous wild-type H9N2 influenza viruses. This vaccine is being evaluated for safety and immunogenicity in clinical trials.

1918 H1N1 pandemic virus

Like the highly pathogenic H5N1 AI viruses, the fully reconstructed recombinant 1918 H1N1 pandemic influenza virus was highly lethal in mice without prior adaptation [131]. The mean time to death in mice infected intranasally was 4.5 days. However, in contrast to the highly pathogenic H5N1 influenza viruses, this virus was not detected in extrapulmonary tissues. Histopathological findings included necrotizing bronchitis and bronchiolitis, moderate to severe alveolitis and severe peribronchial and alveolar edema.

The mouse model appears to be potentially useful for the evaluation of pandemic influenza vaccines. Most AI viruses studied in mice to date can replicate without adaptation, although the outcome of infection with some AI viruses is clearly different depending not only on the particular virus being studied, but also on the laboratory in which the studies were conducted. It is important that AI viruses continue to be evaluated in mice, using standardized inoculation procedures and doses, with measurement of the same endpoints, so that the utility of this model can be maximized for the evaluation of pandemic influenza vaccines.

Ferrets

H5N1 viruses and vaccines

The ability of a limited number of AI subtypes to replicate and cause disease in ferrets has been investigated and, not surprisingly, the behavior of H5 subtype viruses has been studied in the most detail. Zitzow and colleagues [132] demonstrated that two H5N1 influenza viruses isolated from human cases of infection in Hong Kong in 1997 were capable of replication not only in the respiratory tract, but also in the brain, spleen and intestines of ferrets. Virus replication was associated with clinical signs of disease such as severe lethargy, sneezing, rhinitis, hind limb paresis and, in some cases, diarrhea, and some H5N1 viruses were lethal to ferrets. However, the hierarchy of severity of disease seen with the different H5N1 1997 isolates in infection of mice was not observed in ferrets: influenza A/HK/483/97 and A/HK/486/97 were equally virulent after intranasal infection of ferrets, whereas the A/HK/483/97 virus was more virulent in mice than the A/HK/486/97 virus was in several studies [100–102, 133]. As with mice, the significance for humans of the disease signs and extrapulmonary replication of H5N1 viruses in ferrets is not clear, par-
ticularly since in the same study, Zitzow et al. reported isolation of a human H3N2 influenza virus from the brain of ferrets following intranasal infection. Similar studies were conducted using human and avian H5N1 viruses isolated in 2004–2005 [104, 134]. Govorkova et al. [134] evaluated four human H5N1 influenza isolates and nine avian H5N1 isolates from Asia from 2004. A wide spectrum of infectivity, severity of disease and lethality was observed in ferrets inoculated with these viruses. The H5N1 viruses isolated from humans, and two of the avian isolates, caused severe disease in ferrets, with some lethality. However, it is difficult to draw general conclusions regarding the behavior of these viruses in this model because small numbers of animals were used (only two animals per group for all but one of the viruses tested), and there was variability in infectivity. For example, although the influenza A/Vietnam/3046/2004 virus caused severe disease in two out of two ferrets inoculated, it was lethal in only one animal, and virus was only recovered from the nasal washes. In contrast, the influenza A/Vietnam/3062/2004 virus, which was also lethal in one out of two ferrets inoculated, was recovered from the lungs, brain, spleen and intestine of these animals. Similarly, Maines et al. [104] evaluated H5N1 isolates from Asia from 2004 in the ferret model. Although different viruses were used in this study compared to that conducted by Govorkova et al. (with the exception of A/Vietnam/1203/2004), similar findings were reported: the human isolates caused severe disease, with some lethality, in ferrets. Again, small numbers of animals were used (three per group for most of the isolates tested) and some variability in infectivity and severity of disease was observed. In the study conducted by Zitzow et al., gross pathological changes observed in ferrets infected with highly virulent HPAI H5N1 viruses included focal areas of redness in the lungs, consolidation of the lungs and rare discoloration of the liver, petechiae on the liver and lesions on the intestines and kidneys [132]. Maines et al. [104] reported the presence of hemorrhage in the adipose tissue surrounding the liver, kidney and bladder in two thirds of infected ferrets. Histopathological findings in the lungs of infected ferrets included acute bronchiolitis, bronchopneumonia, interstitial pneumonia, with suppurative exudates in the bronchi, bronchioles and adjacent alveolar spaces, with prominent epithelial necrosis and marked intraalveolar edema, by day 3 p.i., and bronchitis, bronchiolitis and pneumonia observed on days 6–7 p.i. [104, 132, 134]. Inflammatory changes were also evident in the brain of ferrets infected with highly virulent HPAI H5N1 viruses, from days 5–6 p.i., including glial nodules, perivascular infiltration of lymphocytes and polymorphonuclear leukocytes in the brain parenchyma, neuronophagia and lymphocytic infiltrates in the choroid plexus [132, 134]. Viral antigen was observed by immunohistochemistry in neurons in the same areas of the brain as the inflammation [104]. Govorkova et al. [134] reported histopathological changes in the liver, including diffuse vacuolization of the hepatocellular cytoplasm, mononuclear infiltrates, periportal hemorrhage, and hepatocellular necrosis. Generally, the viruses isolated from avian species caused less severe disease than those isolated from humans.
The number of ferrets inoculated with each virus was small and ferrets are an outbred species so the significance of variability in data such as virus replication and clinical illness are difficult to interpret. Until the scientific community has more experience with the behavior of AI viruses in animal models, it would be prudent to compare new isolates with well-characterized strains and to study these pathogens in more than one model.

The ferret model has been used to evaluate the efficacy of several experimental inactivated [135, 136] and live attenuated [65, 112, 113] vaccines against H5N1 influenza. Inactivated H5N1 vaccines were immunogenic and protective in the ferret model [135, 136]. However, inactivated H5N1 vaccines that were tested in clinical trials were suboptimally immunogenic [109, 110]. The attenuation of cold-adapted live attenuated H5N1 vaccines was demonstrated in ferrets. These vaccine candidates were also immunogenic and protective against challenge with homologous and heterologous H5N1 wild-type viruses in ferrets [65]. Whether the observations of attenuation and cross-reactive immune responses in ferrets are borne out in clinical studies in humans remains to be seen. Clinical evaluation of the safety and immunogenicity of these vaccines is currently underway.

Protection from lethal H5N1 infection and level of replication of the challenge virus in the lungs and other tissues are the endpoints used for evaluation of efficacy in this model. Van Riel et al. [137] demonstrated that the pattern of attachment of H5N1 influenza human isolates in the respiratory tract of ferrets was similar to that seen in the human respiratory tract, whereby virus attached predominantly to type II pneumocytes, alveolar macrophages and nonciliated cuboidal epithelial cells of the terminal bronchioles in the lower respiratory tract, and became progressively rarer more proximally in the respiratory tract, towards the trachea. This pattern of H5N1 virus attachment predominantly to the lower respiratory tract is thought to be related to the distribution of α-2,3 sialic acid receptors [138]. However, other investigators found that H5N1 influenza viruses were able to infect ex vivo cultures of the human upper respiratory tract, i.e., nasopharyngeal, adenoid and tonsillar tissues, despite a lack of α-2,3 sialic acid receptors in these tissues [139]. The tropism of H5N1 influenza viruses in the respiratory tract of humans and other species remains equivocal and further studies in which a number of different isolates are evaluated in larger numbers of animals are needed.

Other AI subtypes

There are only isolated reports in the literature that describe the replication and clinical signs resulting from infection of ferrets with other AI subtypes. Hinshaw et al. [140] demonstrated that AI viruses of the H2, H3, H6, H7 and H10 subtypes, as well as an H7N7 virus isolated from a seal, replicated in the upper respiratory tract of ferrets, but elicited low or undetectable
levels of antibody. None of these AI isolates tested caused signs of disease in infected ferrets.

Joseph et al. [114] evaluated the immunogenicity of H7 AI viruses in ferrets and demonstrated that the pattern of antigenic relatedness of the viruses studied was similar to that observed in mice.

1918 H1N1 pandemic virus

The reconstructed 1918 H1N1 influenza virus replicated to high titers in the upper respiratory tract of ferrets following intranasal inoculation [141]. All inoculated ferrets exhibited severe signs of disease that included lethargy, anorexia, sneezing, rhinorrhea, severe weight loss and high fever from day 2 p.i., and two out of three animals succumbed to infection by day 11. Unlike the highly pathogenic H5N1 viruses in ferrets, viral replication was not detected in tissues outside the respiratory tract. Necrotizing bronchiolitis, moderate to severe alveolitis and edema were observed in the lungs of infected ferrets on day 3 p.i. The presence of viral antigen in the upper and lower portions of the bronchi, bronchial and bronchiolar epithelium and hyperplastic epithelium within the alveoli was observed.

Cats

There are few reports in the literature on influenza infection in cats. In studies conducted by Paniker and Nair in the 1970s [142, 143], intranasal infection of anesthetized cats with influenza A/Hong/Kong/1968 (H3N2) virus freshly isolated from human cases or laboratory- and egg-adapted isolates did not result in clinical signs of influenza but virus was recovered from pharyngeal secretions, and infection induced HAI antibodies and was transmitted to contact animals. Infected cats did not display clinical signs of influenza. Hinshaw and colleagues [140] later demonstrated that intranasally administered H7N7 and H7N3 AI viruses replicated in the upper respiratory tract of cats without clinical signs of disease, and the cats developed HAI antibodies after infection.

H5N1 AI viruses

There was little interest in influenza infection and immunity in cats until the recent re-emergence of highly pathogenic avian H5N1 viruses in Asia, when it was reported that a number of big cats, namely tigers and leopards, in zoos in Thailand, became infected with HPAI H5N1 viruses, apparently after they were fed infected chicken carcasses [9]. Infection in many of these felids was fatal, and later anecdotal reports of H5N1 infection in domestic
cats in areas where there were outbreaks of H5N1 infection in avian populations contributed to a surge in interest in H5N1 influenza in cats. The pattern of attachment of a human H5N1 influenza virus to respiratory tract tissues of a cat was similar to that seen with human tissue [137].

Experimental infection of European short-haired cats with an H5N1 virus isolated from a human in Vietnam in 2004 resulted in clinical disease, virus replication in respiratory and extra-pulmonary tissues, and pathological changes consistent with H5N1 infections in humans [10, 144]. Clinical signs, including significant elevation in body temperature, decreased activity, conjunctivitis and labored breathing were seen in experimentally infected cats that were infected intratracheally or by feeding on infected chicks [10]. Similar disease symptoms were observed in sentinel cats that became infected from being housed with cats that had been infected intratracheally. Illness in contact cats became apparent about 3 days later than in the cats infected via the intratracheal route. Peak viral titers in throat swabs of intratracheally infected cats were ~ $10^{4.5}\text{ TCID}_{50}/\text{ml}$, whereas the peak titers observed in nasal swabs ranged from $10^{2.5}$ to $10^{3.0}\text{ TCID}_{50}/\text{ml}$ [144]. Virus was also recovered from rectal swabs of cats infected by feeding on infected chicks, but the titers of virus in these samples varied widely. In addition, cats infected through feeding had lesions in the intestines. In animals infected intratracheally or by feeding, virus was also recovered from extra-pulmonary tissues, most often from the brain, liver, kidney and heart. Infected sentinel cats did not have detectable virus in tissues outside the respiratory tract; however, pathological changes were observed in the adrenal glands in one of the two sentinel cats infected in this manner. These studies demonstrated that HPAI H5N1 viruses are capable of extrapulmonary spread in cats, and can cause severe disease and even death in animals infected intratracheally or by feeding on infected bird carcasses. The observations also raise the possibility that HPAI H5N1 influenza in cats may be spread from the gastrointestinal tract.

Karaca et al. [145] reported studies on the immunogenicity of a fowlpox-based H5 vaccine in cats. HAI antibodies were detected in serum of cats following a single subcutaneous dose of vaccine, and a significant boost in antibody titers was observed following a second vaccination.

It remains to be seen whether cats will be used extensively in the evaluation of pandemic influenza vaccines.

**Hamsters**

**H9 viruses and vaccines**

Saito and colleagues conducted a study to evaluate the replication and pathogenicity of influenza viruses of various subtypes in Syrian hamsters [146]. The influenza A/HK/1073/99 (H9N2) virus replicated to high titers in
the lungs, but was not lethal to hamsters and was not detected in the brain. The HPAI H5N1 influenza A/HK/483/97 virus that was highly virulent in mice was also lethal in hamsters, with all animals succumbing to infection by day 6 p.i., and, as in mice, virus was recovered from the brain of infected hamsters. Avian H9N2 and H9N5 isolates replicated in the lungs of hamsters, but to lower titers than human isolates. The human H9N2 virus elicited low levels of neutralizing antibody in infected hamsters, whereas the avian H9N2 isolate did not elicit detectable neutralizing antibody. The behavior of this limited number of AI isolates in the Syrian hamster model suggest that these viruses may be similar to that observed in mice, and further evaluation of this model for evaluating the efficacy of pandemic influenza vaccines is warranted.

Non-human primates

There is renewed interest in the use of non-human primates for immunogenicity studies for pandemic vaccines, based on the presumption that immune responses in these animals, having a closer evolutionary relationship to humans, may be more predictive of the responses in humans than smaller animals like mice and ferrets. To date, there are few data available on the serological responses in non-human primates to AI virus vaccines.

H5N1 AI viruses

The use of cynomolgus macaques as a model for influenza virus infection in humans was revisited following the emergence of the highly pathogenic H5N1 AI viruses in 1997 [147]. The initial human H5N1 influenza isolate, A/Hong Kong/156/1997, isolated from a fatal case of influenza in a child [7], was inoculated at multiple sites, including the trachea, tonsils and conjunctiva. Three of four animals developed fever within 2 days, and one showed signs of anorexia and acute respiratory distress. High titers of virus were recovered from lungs on day 4 p.i., and virus was also isolated from the trachea, tracheobronchial lymph nodes and heart. Virus was not recovered from these tissues on day 7 p.i. Virus was also recovered from bronchoalveolar lavage from two out of two animals on days 3 and 5 p.i.; from pharyngeal swabs from two animals on day 5 p.i., and from nasal swabs from one animal on days 3 and 7. Viral RNA was detected in the brains of two animals by RT-PCR on day 4 p.i., and in the spleen of all four animals tested on day 7 p.i. Pathological changes in the lungs of infected animals included pulmonary consolidation, necrotizing broncho-interstitial pneumonia and flooding of alveoli with edema fluid, fibrin, erythrocytes, cell debris, macrophages and neutrophils and inflammatory changes were seen in multiple organs [148].
Infection of Rhesus macaques with avian H5N1 isolates reported by Chen et al. [149] indicated that results of intranasal inoculation varied depending on the influenza virus isolate used. Clinical signs of infection, including elevation in body temperature, anorexia and increased respiratory rate were observed in macaques inoculated with the following H5N1 viruses: A/bar-headed goose/Qinghai/1/2005, A/great cormorant/Qinghai/3/2005 and A/duck/Guangxi/35/2001. Pathological changes were seen in the lungs of all infected animals, but were more pronounced in the monkeys inoculated with the duck isolate. However, the only virus to be re-isolated from infected animals was A/duck/Guangxi/35/2001, and this virus was isolated from respiratory tract secretions and tissues and also from spleen, liver and heart.

1918 H1N1 pandemic virus

Cynomolgus macaques were evaluated as a model for the reconstructed 1918 H1N1 pandemic influenza virus [150]. Monkeys were infected by multiple routes – intratracheally, orally, on the tonsils and conjunctiva – based on the earlier studies with HPAI H5N1 influenza viruses in this species [147]. Animals infected with the reconstructed 1918 virus had severe clinical illness, high levels of virus replication in the respiratory tract and severe pathological changes in the lungs, compared to control animals infected with a recombinant human H1N1 influenza virus, A/Kawasaki/173/01 [150].

There may be a place for non-human primates in the evaluation of pandemic influenza vaccines, but the currently available data are not sufficient to support the use of these models for immunogenicity or efficacy studies. Further studies are needed to characterize AI infection and the immune responses to AI viruses and vaccines in these species.

**Correlates of protection from AI viruses and regulatory concerns**

Despite the fact that the correlates of protection from AI virus infections in humans are not known, the criteria for licensing pandemic influenza vaccines are based on the previous human experience with vaccines against seasonal influenza. In Europe and the United States, regulatory authorities have published guidance for vaccine manufacturers that attempt to balance the need for expedited approval of pandemic influenza vaccines with the requirements of demonstration of safety and immunogenicity of candidate vaccines.

In the United States, for example, a guidance for vaccine manufacturers was published in 2007 [151], which states that licensure of both inactivated and live attenuated vaccines for pandemic influenza should be based on the percent of subjects achieving an HAI antibody titer of 1:40 or greater, and upon the rate of seroconversion, which is defined as a fourfold or greater rise
in post-vaccination HAI antibody titer. Efficacy studies in animal models, although not an absolute requirement, may at least provide evidence that biologically relevant immune responses are elicited by candidate vaccines.

This guidance is intended to allow for the rapid marketing approval of pandemic influenza vaccines that are produced using manufacturing processes that are already validated for seasonal influenza vaccines, so that the licensure of the pandemic vaccine is essentially a strain change. Such approval requires much more limited testing of the candidate vaccines in animal models. In the European Union, manufacturers are required to submit information on the production and pre-clinical testing of a ‘mock-up’ pandemic vaccine. In the event of a pandemic, a vaccine made in the same way as the mock-up vaccine, but based on the nascent pandemic virus, will be produced and will be subject to limited pre-clinical characterization, including immunogenicity studies in animals on at least one batch of the product [152]. Efficacy studies of the actual pandemic vaccine formulation in animals are not required. However, extensive pre-clinical testing of the vaccine candidate is required for new vaccine modalities and formulations, including formulation of approved vaccines with adjuvants.

In the United States, a regulatory mechanism was introduced under what is commonly referred to as the ‘animal rule’ [153] for marketing approval of vaccines for which efficacy studies in healthy human volunteers are either unethical or not feasible. This regulation stipulates that, in cases where efficacy of vaccines in humans cannot be definitively determined, marketing approval for a vaccine may be granted based on ‘adequate and well-controlled animal studies’ providing that the basis for vaccine efficacy is reasonably well understood, and that the animal responds to the vaccine in a manner that is predictive for humans. Studies in more than one animal species would typically be required, unless a single animal model is available that faithfully predicts efficacy in humans. It is unclear at this time whether this rule will eventually be applied to vaccines for pandemic influenza. In any event, it is critical that the predictive value of the available animal models for immunogenicity and efficacy of pandemic influenza vaccines be determined systematically using the same vaccine formulations that are progressing into clinical studies.

Conclusion

Although several animal species support the replication of human and AI viruses, a survey of the literature leads to the conclusion that there is no single ideal animal model for the evaluation of influenza vaccines. Some animal models are more suitable than others to predict the attenuation of live virus vaccines, or more closely reflect the human immune response to vaccines. Animal models certainly play a crucial role in the evaluation of influenza vaccines, but the limitations of the models must be taken into account
when decisions are made regarding which vaccine candidates should move forward into clinical trials.

The evaluation of vaccines for pandemic influenza presents additional challenges in that the correlates of protection from AI viruses are not known, and so there may be a greater need for reliance on data from animal studies for these vaccines. It is critical that the behavior of AI viruses with pandemic potential be characterized in a range of animal models. Even from limited observations it is clear that replication of AI viruses and their ability to cause disease in animals depends on the host species, and is subtype and even strain specific. Therefore, pre-clinical safety, immunogenicity and efficacy data from animal studies must be carefully considered in the evaluation of pandemic influenza vaccines.

Acknowledgements

We thank Brian Murphy for critical review of this manuscript. This research was supported in part by the Intramural Research Program of the NIAID, NIH.

References

1 Palese P, Shaw ML (2007) Orthomyxoviridae: The viruses and their replication. In: DM Knipe, PM Howley, DE Griffin, RA Lamb, MA Martin, B Roizman, SE Straus (eds): Field Virology (5th ed), Lippincott Williams and Wilkins, Philadelphia, 1647–1689
2 Wright PF, Neumann G, Kawaoka Y (2007) Orthomyxoviruses. In: DM Knipe, PM Howley, DE Griffin, RA Lamb, MA Martin, B Roizman, SE Straus (eds): Fields Virology, 5th edn. Lippincott Williams & Wilkins, Philadelphia, 1691–1740
3 Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, Smith D, Rimmelzwaan GF, Olsen B, Osterhaus AD (2005) Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 79: 2814–2822
4 Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y (1992) Evolution and ecology of Influenza A viruses. Microbiol Rev 56: 152–179
5 Cox NJ, Subbarao K (2000) Global epidemiology of influenza: Past and present. Annu Rev Med 51: 407–421
6 Meltzer MI, Cox NJ, Fukuda K (1999) The economic impact of pandemic influenza in the United States: Priorities for intervention. Emerg Infect Dis 5: 659–671
7 Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J et al (1998) Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279: 393–396
8 Kawaoka Y, Krauss S, Webster RG (1989) Avian-to-human transmission of the
PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. *J Virol* 63: 4603–4608

9 Keawcharoen J, Oraveerakul K, Kuiken T, Fouchier RA, Amonsin A, Payungporn S, Noppornpan S, Wattanodor S, Theambooniers A, Tantilertcharoen R et al (2004) Avian influenza H5N1 in tigers and leopards. *Emerg Infect Dis* 10: 2189–2191

10 Kuiken T, Rimmelzwaan G, van Riel D, van Amerongen G, Baars M, Fouchier R, Osterhaus A (2004) Avian H5N1 influenza in cats. *Science* 306: 241

11 Couch RB, Kasel JA (1983) Immunity to influenza in man. *Annu Rev Microbiol* 37: 529–549

12 Hobson D, Curry RL, Beare AS, Ward-Gardner A (1972) The role of serum hemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. *J Hyg* 70: 767–777

13 Treanor J, Wright PF (2003) Immune correlates of protection against influenza in the human challenge model. In: F Brown, LR Haaheim, GC Schild (eds): *Laboratory Correlates of Immunity to Influenza – A Reassessment*. Karger, Basel, 97–104

14 Clements ML, Murphy BR (1986) Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. *J Clin Microbiol* 23: 66–72

15 Gorse GJ, O’Connor TZ, Newman FK, Mandava MD, Mendelman PM, Wittes J, Peduzzi PN (2004) Immunity to influenza in older adults with chronic obstructive pulmonary disease. *J Infect Dis* 190: 11–19

16 Murphy BR, Coelingh K (2002) Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. *Viral Immunol* 15: 295–323

17 Smith W, Andrewes CH, Laidlaw PP (1933) A virus obtained from influenza patients. *Lancet* II: 66–68

18 Andrewes CH, Laidlaw PP, Smith W (1934) The susceptibility of mice to the viruses of human and swine influenza. *Lancet* II: 859–862

19 Brown EG (1990) Increased virulence of a mouse-adapted variant of Influenza A/FM/1/47 virus is controlled by mutations in genome segments 4, 5, 7 and 8. *J Virol* 64: 4523–4533

20 Brown EG, Liu H, Chang Kit L, Baird S, Nesrallah M (2001) Pattern of mutation in the genome of influenza A virus on adaptation to increased virulence in the mouse lung: Identification of functional themes. *Proc Natl Acad Sci USA* 98: 6883–6888

21 Smeenk CA, Brown EG (1994) The Influenza virus variant A/FM/1/47–MA possesses single amino acid replacements in the hemagglutinin, controlling virulence, and in the matrix protein, controlling virulence as well as growth. *J Virol* 68: 530–534

22 Smeenk CA, Wright KE, Burns BF, Thaker AJ, Brown EG (1996) Mutations in the hemagglutinin and matrix genes of a virulent influenza virus variant, A/FM/1/47–MA, control different stages in pathogenesis. *Virus Res* 44: 79–95

23 Grimm D, Staeheli P, Hufbauer M, Koerner I, Martinez-Sobrido L, Solorzano A, Garcia-Sastre A, Haller O, Kochs G (2007) Replication fitness determines
high virulence of influenza A virus in mice carrying functional Mx resistance gene. *Proc Natl Acad Sci USA* 104: 6806–6811

24 Epstein SL, Lo CY, Misplon JA, Lawson CM, Hendrickson BA, Max EE, Subbarao K (1997) Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, β2-microglobulin-deficient, and J chain-deficient mice. *J Immunol* 158: 1222–1230

25 Tumpey TM, Szretter KI, Van Hoeven N, Katz JM, Kochs G, Haller O, Garcia-Sastre A, Staeheli P (2007) The Mx1 gene protects mice against pandemic 1918 and highly lethal human H5N1 influenza viruses. *J Virol* 81: 10818–10821

26 Virelizier J (1975) Host defenses against influenza virus: The role of anti-hemagglutinin antibody. *J Immunol* 115: 434–439

27 Ramphal R, Cogliano RC, Shands JW, Small PAJ (1979) Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis. *Infect Immun* 25: 992–997

28 Takiguchi K, Sugawara K, Hongo S, Nishimura H, Kitame F, Nakamura K (1992) Protective effect of serum antibody on respiratory infection of influenza C virus in rats. *Arch Virol* 122: 1–11

29 Prince GA, Horswood RL, Chanock RM (1985) Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. *J Virol* 55: 517–520

30 Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, Packard M, Shieh WJ, Zaki S, Murphy B (2004) Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. *J Virol* 78: 3572–3577

31 Iida T, Bang FB (1963) Infection of the upper respiratory tract of mice with influenza virus. *Am J Hyg* 77: 169–176

32 Yetter RA, Lehrer S, Ramphal R, Small PAJ (1980) Outcome of influenza infection: Effect of site of initial infection and heterotypic immunity. *Infect Immun* 29: 654–662

33 Staeheli P, Grob R, Meier E, Sutcliffe JG, Haller O (1988) Influenza virus-susceptible mice carry Mx genes with a large deletion or a nonsense mutation. *Mol Cell Biol* 8: 4518–4523

34 Staeheli P, Haller O, Boll W, Lindenmann J, Weissmann C (1986) Mx protein: Constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers selective resistance to influenza virus. *Cell* 44: 147–158

35 Abou-Donia H, Jennings R, Potter CW (1980) Growth of influenza A viruses in hamsters. *Arch Virol* 65: 99–107

36 Heath AW, Addison C, Ali M, Teale D, Potter CW (1983) *In vivo* and *in vitro* hamster models in the assessment of virulence of recombinant influenza viruses. *Antiviral Res* 3: 241–252

37 Murphy BR, Wood FT, Massicot JG, Chanock RM (1978) Temperature-sensitive mutants of influenza virus. XVI. Transfer of the two ts lesions present in the Udonm/72-ts-1A2 donor virus to the Victoris/3/75 wild-type virus. *Virology* 88: 244–251

38 Subbarao EK, Kawaoka Y, Murphy BR (1993) Rescue of an influenza A virus wild-type PB2 gene and a mutant derivative bearing a site-specific temperature-sensitive and attenuating mutation. *J Virol* 67: 7223–7228
39 Phair JP, Kauffman CA, Jennings R, Potter CW (1979) Influenza virus infection of the guinea pig: Immune response and resistance. Med Microbiol Immunol 165: 241–254

40 Azoulay-Dupuis E, Lambre CR, Soler P, Moreau J, Thibon M (1984) Lung alterations in guinea-pigs infected with influenza virus. J Comp Pathol 94: 273–283

41 Lowen AC, Mubareka S, Tumpey TM, Garcia-Sastre A, Palese P (2006) The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci USA 103: 9988–9992

42 Ali M, Maassab HF, Jennings R, Potter CW (1982) Infant rat model of attenuation for recombinant influenza viruses prepared from cold-adapted attenuated A/Ann/Arbor/6/60. Infect Immun 38: 610–619

43 Mahmud MIA, Jennings R, Potter CW (1979) The infant rat as a model for assessment of the attenuation of human influenza viruses. J Med Microbiol 12: 43–54

44 Teh C, Jennings R, Potter CW (1980) Influenza virus infection of newborn rats: Virulence of recombinant strains prepared from influenza virus strain A/Okuda/57. J Med Microbiol 13: 297–306

45 Niewiesk S, Prince G (2002) Diversifying animal models: The use of hispid cotton rats (Sigmodon hispidus) in infectious diseases. Lab Anim 36: 357–372

46 Sadowski W, Wilczynski J, Semkow R, Tulinowska M, Krus S, Kantoch M (1987) [The cotton rat (Sigmodon hispidus) as an experimental model for studying viruses in respiratory tract infections. II. Influenza viruses types A and B]. Med Dosw Mikrobiol 39: 43–55

47 Ottolini MG, Blanco JC, Eichelberger MC, Porter DD, Pletneva L, Richardson JY, Prince GA (2005) The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis. J Gen Virol 86: 2823–2830

48 Burnet FM (1941) Influenza virus “A” infections of cynomolgus monkeys. Aust J Exp Biol Med Sci 19: 281–290

49 Saslaw S, Wilson HE, Doan CA, Woolpert OC, Schwab JL (1946) Reactions of monkeys to experimentally induced influenza virus A infection. An analysis of the relative roles of humoral and cellular immunity under conditions of optimal or deficient nutrition. J Exp Med 84: 113–125

50 Rimmelzwaan GF, Baars M, van Beek R, Van Amerongen G, Lovgren-Bengtsson K, Claas EJC, Osterhaus ADME (1997) Induction of protective immunity against influenza virus in a macaque model: Comparison of conventional and ISCOM vaccines. J Gen Virol 78: 757–765

51 Baskin CR, Garcia-Sastre A, Tumpey TM, Bielefeldt-Ohmann H, Carter VS, Nistal-Villan E, Katze MG (2004) Integration of clinical data, pathology, and cDNA microarrays in influenza virus-infected pigtailed macaques (Macaca nemestrina). J Virol 78: 10420–10432

52 Murphy BR, Lewis Sly D, Hosier NT, London WT, Chanock RM (1980) Evaluation of three strains of influenza A virus in humans and in owl, cebus and squirrel monkeys. Infect Immun 28: 688–691

53 Murphy BR, Hinshaw VS, Lewis Sly D, London WT, Hosier NT, Wood FT, Webster RG, Chanock RM (1982) Virulence of avian influenza A viruses for squirrel monkeys. Infect Immun 37: 1119–1126
54 Snyder MH, Clements ML, Herrington D, London WT, Tierney EL, Murphy BR (1986) Comparison by studies in squirrel monkeys, chimpanzees, and adult humans of avian-human Influenza A virus reassortants derived from different avian influenza virus donors. J Clin Microbiol 24: 467–469
55 Grizzard MB, London WT, Sly DL, Murphy BR, James WD, Parnell WP, Chanock RM (1978) Experimental production of respiratory tract disease in cebus monkeys after intratracheal or intranasal infection with influenza A/Victoria/3/75 or influenza A/New Jersey/76 virus. Infect Immun 21: 201–205
56 Murphy BR, Hall SL, Crowe J, Collins PL, Subbarao EK, Connors M, London WT, Chanock RM (1992) The use of chimpanzees in respiratory virus research. In: J Erwin, JC Landon (eds): Chimpanzee Conservation and Public Health: Environments for the Future. Diagnon/Bioqual, Rockville
57 Snyder MH, London WT, Tierney EL, Maassab HF, Murphy BR (1986) Restricted replication of a cold-adapted reassortant influenza A virus in the lower respiratory tract of chimpanzees. J Infect Dis 154: 370–371
58 WHO (2005) WHO Guidelines on nonclinical evaluation of vaccines. Annex 1, World Health Organization
59 Sugg JY (1949) An influenza virus pneumonia of mice that is nontransferable by serial passage. J Bacteriol 57: 399–403
60 Henle W, Henle G (1946) Studies on the toxicity of influenza viruses. II. The effect of intra-abdominal and intravenous injection of influenza viruses. J Exp Med 84: 639–661
60a Jin H, Manetz S, Leininger J, Luke C, Subbarao K, Murphy B, Kemble G, Coelingh KL (2007) Toxicological evaluation of live attenuated cold-adapted H5N1 vaccines in ferrets. Vaccine 25: 8664–8672
61 Betts RF, Douglas GRJ, Maassab HF, DeBorde DC, Clements ML, Murphy BR (1988) Analysis of virus and host factors in a study of A/Peking/2/79 (H3N2) cold-adapted vaccine recombinant in which vaccine-associated illness occurred in normal volunteers. J Med Virol 26: 175–183
62 Murphy BR, Holley HP, Berquist EJ, Levine MM, Spring SB, Maassab HF, Kendal AP, Chanock RM (1979) Cold-adapted variants of influenza A virus: Evaluation in adult seronegative volunteers of A/Scotland/840/74 and A/Victoria/3/75 cold-adapted recombinants derived from the cold-adapted A/Ann Arbor/6/60 strain. Infect Immun 23: 253–259
63 Okuno Y, Nakamura K, Yamamura T, Takahashi M, Toyota K, Kunita N, Sugai T, Fujita T (1960) Studies on attenuation of influenza virus. Proc Jpn Acad 36: 299–303
64 Center for Biologics Evaluation and Research (CBER), 21 CFR PART 610 General Biological Products Standards (Food and Drug Administration)
65 Suguitan AL J, Jr, McAuliffe J, Mills KL, Jin H, Duke G, Lu B, Luke CJ, Murphy B, Swayne DE, Kemble G, Subbarao K (2006) Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3: e360
66 WHO (2003) Production of pilot lots of inactivated influenza vaccines from reassortants derived from avian influenza viruses. Interim biosafety risk assessment. World Health Organization
Gonin P, Gaillard C (2002) Gene transfer vector biodistribution: Pivotal safety studies in clinical gene therapy development. *Gene Ther* 11: S98–S108

Leamy VL, Martin T, Mahajan R, Vilalta A, Rusalov D, Hartikka J, Bozoukova V, Hall KD, Morrow J, Rolland AP et al (2006) Comparison of rabbit and mouse models for persistence analysis of plasmid-based vaccines. *Hum Vaccines* 2: 113–118

Ledwith BJ, Manam S, Troilo PJ, Barnum AB, Pauley CJ, Griffiths TG, Harper LB, Schock HB, Zhang H, Faris JE et al (2002) Plasmid DNA vaccines: Assay for integration into host genomic DNA. *Dev Biol* 104: 33–43

Manam S, Ledwith BJ, Barnum AB, Troilo PJ, Pauley CJ, Harper LB, Griffiths TG, Niu Z, Denisova L, Follmer TT et al (2000) Plasmid DNA vaccines: Tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. *Intervirology* 43: 273–281

Winegar RA, Monforte JA, Suing KD, O’Loughlin KG, Rudd CJ, Macgregor JT (1996) Determination of tissue distribution of an intramuscular plasmid vaccine using PCR and in situ DNA hybridization. *Hum Gene Ther* 7: 2185–2194

Maassab HF, Kendal AP, Abrams GD, Monto AS (1982) Evaluation of a cold-recombinant influenza virus vaccine in ferrets. *J Infect Dis* 146: 780–790

Murphy BR, Sly DL, Tierney EL, Hosier NT, Massicot JG, London WJ, Chanock RM, Webster RG, Hinshaw VS (1982) Reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys. *Science* 218: 1330–1332

EMEA (2003) *Points to Consider on the Development of Live Attenuated Influenza Vaccines*. European Agency for the Evaluation of Medicinal Products, CPMP/BWP/2289/01

Rubin SA, Liu D, Pletnikov M, McCullers JA, Ye Z, Levandowski RA, Johannessen J, Carbone KM (2004) Wild-type and attenuated influenza virus infection of the neonatal rat brain. *J Neurovirol* 10: 305–314

Smith W, Andrewes CH, Laidlaw PP (1935) Influenza: Experiments on the immunization of ferrets and mice. *Br J Exp Pathol* 16: 291–302

Potter CW, Oxford JS, Shore SL, McLaren C, Stuart-Harris CH (1972) Immunity to influenza in ferrets. I. Response to live and killed virus. *Br J Exp Pathol* 53: 153–167

Potter CW, Shore SL, McLaren C, Stuart-Harris CH (1972) Immunity to influenza in ferrets. 2. Influence of adjuvants on immunization. *Br J Exp Pathol* 53: 168–179

Benton KA, Misplon JA, Lo CY, Brutkiewicz RR, Prasad SA, Epstein SL (2001) Heterosubtypic immunity to Influenza A virus in mice lacking IgA, all Ig, NKT cells or gd T cells. *J Immunol* 166: 7437–7445

Epstein SL, Lo CY, Misplon JA, Bennink JR (1998) Mechanism of protective immunity against influenza virus infection in mice without antibodies. *J Immunol* 160: 322–327

Epstein SL, Lo CY, Misplon JA, Lawson CM, Hendrickson BA, Max EE, Subbarao K (1997) Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, β2-microglobulin-deficient, and J chain-deficient mice. *J Immunol* 158: 1222–1230

Nguyen HH, van Ginkel FW, Vu HL, McGhee JR, Mestecky J (2001)
Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. *J Infect Dis* 183: 368–376

Nguyen HH, Zemlin M, Ivanov II, Andrasi J, Zemlin C, Vu HL, Schelonka R, Schroeder HWJ, Mestecky J (2007) Heterosubtypic immunity to influenza A virus infection requires a properly diversified antibody repertoire. *J Virol* 81: 9331–9338

McLaren C, Potter CW (1974) Immunity to influenza in ferrets. VII. Effect of previous infection with heterotypic and heterologous influenza viruses on the response of ferrets to inactivated influenza virus vaccines. *J Hyg* 72: 91–100

McLaren C, Potter CW, Jennings R (1974) Immunity to influenza in ferrets. X. Intranasal immunization of ferrets with inactivated influenza A virus vaccines. *Infect Immun* 9: 985–990

Yetter RA, Barber WH, Small PAJ (1980) Heterotypic immunity to influenza in ferrets. *Infect Immun* 29: 650–653

Straight TM, Ottolini MG, Prince GA, Eichelberger MC (2006) Evidence of a cross-protective immune response to influenza A in the cotton rat model. *Vaccine* 24: 6264–6271

Epstein SL (2006) Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957. *J Infect Dis* 193: 49–53

Steinhoff MC, Fries LF, Karron RA, Clements ML, Murphy BR (1993) Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children. *J Clin Microbiol* 31: 836–838

Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, Subbarao K, Renshaw M, Sambhara S, Katz JM (2002) DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. *Emerg Infect Dis* 8: 796–801

Okuda K, Ihata A, Watabe S, Okada E, Yamakawa T, Hamajima K, Yang J, Ishii N, Nakazawa M, Okuda K et al (2001) Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. *Vaccine* 19: 3681–3691

Ulmer J, Donnelly J, Parker S, Rhodes G, Felgner P, Dwarki V, Gromkowski S, Deck R, DeWitt C, Friedman A et al (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. *Science* 259: 1745–1749

Slepuchkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ (1995) Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. *Vaccine* 13: 1399–1402

Fan J, Liang X, Horton M, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przybyckie CT, Keller PM et al (2004) Preclinical study of influenza virus A M2 peptide conjugate in mice, ferrets, and rhesus monkeys. *Vaccine* 22: 2993–3003

DeFilette M, Friers W, Martens W, Birkett A, Ramne A, Lowenadler B, Lycke N, Jou WM, Saelens X (2006) Improved design and intranasal delivery of an M2e-based human influenza A vaccine. *Vaccine* 24: 6597–6601

DeFilette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Friers W (2005) Universal influenza A vaccine: Optimization of M2-based constructs. *Virology* 337: 149–161
97 Neiryneck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Friers W (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. *Nat Med* 5: 1157–1163

98 Sandbote MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ (2007) Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. *PLoS Med* 4: e59

99 Murphy BR, Kasel JA, Chanock RM (1972) Association of serum anti-neuraminidase antibody with resistance to influenza in man. *N Engl J Med* 286: 1329–1332

100 Gao P, Watanabe S, Ito T, Goto H, Wells K, McGregor M, Cooley AJ, Kawaoka Y (1999) Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong. *J Virol* 73: 3184–3189

101 Katz JM, Lu X, Tumpey TM, Smith CB, Shaw MW, Subbarao K (2000) Molecular correlates of influenza A H5N1 virus pathogenesis in mice. *J Virol* 74: 10807–10810

102 Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, Katz JM (1999) A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. *J Virol* 73: 5903–5911

103 Dybing JK, Schultz-Cherry S, Swayne DE, Suarez DL, Perdue ML (2000) Distinct pathogenesis of Hong Kong-origin H5N1 viruses in mice compared to that of other highly pathogenic H5 avian influenza viruses. *J Virol* 74: 1443–1450

104 Maines TR, Lu XH, Erb SM, Edwards L, Guarner J, Greer PW, Nguyen DC, Szretter KJ, Chen LM, Thawatsupha P et al (2005) Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. *J Virol* 79: 11788–11800

105 Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza. *Lancet* 357: 1937–1943

106 Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zambon M (2003) Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. *Vaccine* 21: 1687–1693

107 Stephenson I, Nicholson KG, Gluck R, Mischler R, Newman RW, Palache, AM, Verlander NQ, Warburton F, Wood JM, Zambon MC (2003) Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: Phase I randomised trial. *Lancet* 362: 1959–1966

108 Subbarao K, Luke CJ (2007) H5N1 viruses and vaccines. *PLoS Pathog* 3: e40

109 Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon MC (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. *Lancet* 367: 1657–1664

110 Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. *N Engl J Med* 354: 1343–1351
111 Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z et al (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: A Phase I randomised controlled trial. *Lancet* 368: 991–997

112 Desheva JA, Lu XH, Rekstins AR, Rudenko LG, Swayne DE, Cox NJ, Katz JM, Klimov AI (2006) Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. *Vaccine* 24: 6859–6866

113 Lu X, Edwards LE, Desheva JA, Nguyen DC, Rekstins AR, Stephenson I, Szretter KJ, Cox NJ, Rudenko LG, Klimov A, Katz JM (2006) Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. *Vaccine* 24: 6588–6593

114 Joseph T, McAuliffe J, Lu B, Jin H, Kemble G, Subbarao K (2007) Evaluation of replication and pathogenicity of avian influenza A H7 subtype viruses in a mouse model. *J Virol* 81: 10558–10566

115 de Wit E, Munster V, Spronken MIJ, Bestebroer TM, Baas C, Beyer WE, Rimmelzwaan GF, Osterhaus ADME, Fouchier RAM (2005) Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain. *J Virol* 79: 12401–12407

116 Munster VJ, de Wit E, van Riel D, Beyer WE, Rimmelzwaan GF, Osterhaus ADME, Kuiken T, Fouchier RAM (2007) The molecular basis of the pathogenicity of the Dutch highly pathogenic human influenza A H7N7 viruses. *J Infect Dis* 196: 258–265

117 Rigoni M, Shinya K, Toffan A, Milani A, Bettini F, Kawaoka Y, Cattoli G, Capua I (2007) Pneumo- and neurotropism of avian origin Italian highly pathogenic avian influenza H7N1 isolates in experimentally infected mice. *Virology* 364: 28–35

118 Guo Y, Li J, Cheng X (1999) [Discovery of men infected by avian influenza A (H9N2) virus]. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi* 13: 105–108

119 Peiris M, Yuen KY, Leung CW, Chan KH, Ip PLS, Lai RWM, Orr WK, Shortridge KF (1999) Human infection with influenza H9N2. *Lancet* 354: 916–917

120 Guan Y, Shortridge KF, Krauss S, Webster RG (1999) Molecular characterization of H9N2 influenza viruses: Were they the donors of the “internal” genes of H5N1 viruses in Hong Kong? *Proc Natl Acad Sci USA* 96: 9363–9367

121 Guo YJ, Krauss S, Senne DA, Mo IP, Lo KS, Xiong XP, Norwood M, Shortridge KF, Webster RG, Guan Y (2000) Characterization of the pathogenicity of members of the newly established H9N2 influenza virus lineages in Asia. *Virology* 267: 279–288

122 Shortridge KF (1999) Poultry and the influenza H5N1 outbreak in Hong Kong, 1997: Abridged chronology and virus isolation. *Vaccine* 17 (Suppl 1): S26–29

123 Xu KM, Li KS, Smith GJ, Li JW, Tai H, Zhang JX, Webster RG, Peiris JS, Chen H, Guan Y (2007) Evolution and molecular epidemiology of H9N2 influenza A viruses from quail in southern China, 2000–2005. *J Virol* 81: 2635–2645

124 Xu KM, Smith GJ, Bahl J, Duan L, Tai H, Vijaykrishna D, Wang J, Zhang JX, Li
KS, Fan XH et al (2007) The genesis and evolution of H9N2 influenza viruses in poultry from southern China, 2000 to 2005. J Virol 81: 10389–10401

125 Leneva IA, Goloubeva O, Fenton RJ, Tisdale M, Webster RG (2001) Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother 45: 1216–1224

126 Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG (2000) The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 48: 101–115

127 Lu X, Renshaw M, Tumpey TM, Kelly GD, Hu-Primmer J, Katz JM (2001) Immunity to influenza A H9N2 viruses induced by infection and vaccination. J Virol 75: 4896–4901

128 Ernst WA, Kim HJ, Tumpey TM, Jansen AD, Tai W, Cramer DV, Adler-Moore JP, Fuji j G (2006) Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24: 5158–5168

129 Chen H, Matsuoka Y, Swayne D, Chen Q, Cox NJ, Murphy BR, Subbarao K (2003) Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 21: 4430–4436

130 Chen H, Subbarao K, Swayne D, Chen Q, Lu X, Katz J, Cox N, Matsuoka Y (2003) Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. Vaccine 21: 1974–1979

131 Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solorzano A, Swayne DE, Cox NJ, Katz JM, Taubenberger JK, Palese P, Garcia-Sastre A (2005) Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310: 77–80

132 Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, Katz JM (2002) Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol 76: 4420–4429

133 Katz JM, Lu X, Frace AM, Morken T, Zaki SR, Tumpey TM (2000) Pathogenesis of and immunity to avian influenza A H5 viruses. Biomed Pharmacother 54: 178–187

134 Govorkova EA, Rehg JE, Krauss S, Yen HL, Guan Y, Peiris M, Nguyen TD, Hanh TH, Puthavathana P, Long HT et al (2005) Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 79: 2191–2198

135 Lipatov AS, Hoffmann E, Salomon R, Yen HL, Webster RG (2006) Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis 194: 1040–1043

136 Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova EA, McCain-Moss LR, Peiris JS, Rehg JE, Tuomanen EI, Webster RG (2004) Responsiveness to a pandemic alert: Use of reverse genetics for rapid development of influenza vaccines. Lancet 363: 1099–1103

137 van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus ADME, Kuiken T (2006) H5N1 virus attachment to lower respiratory tract. Science 312: 399
The role of animal models in influenza vaccine research

138 Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y (2006) Influenza virus receptors in the human airway. Nature 440: 435–436

139 Nicholls JM, Chan MCW, Chan WY, Wong HK, Cheung CY, Kwong DLW, Wong MP, Chui WH, Poon LLM, Tsao SW et al (2007) Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat Med 13: 147–149

140 Hinshaw VS, Webster RG, Easterday BC, Bean WJ (1981) Replication of avian influenza A viruses in mammals. Infect Immun 34: 354–361

141 Tumpey TM, Maines TR, Van Hoeven N, Glaser L, Solorzano A, Pappas C, Cox NJ, Swayne DE, Palese P, Katz JM, Garcia-Sastre A (2007) A two-amin acid change in the hemagglutinin of the 1918 Influenza virus abolishes transmission. Science 315: 655–659

142 Paniker CKJ, Nair CMG (1970) Infection with A2 Hong Kong influenza virus in domestic cats. Bull World Health Organ 43: 859–862

143 Paniker CKJ, Nair CMG (1972) Experimental infection of animals with influenza-virus types A and B. Bull World Health Organ 47: 461–463

144 Rimmelzwaan GF, van Riel D, Baars M, Bestebroer TM, van Amerongen G, Fouchier RA, Osterhaus AD, Kuiken T (2006) Influenza A virus (H5N1) infection in cats causes systemic disease with potential novel routes of virus spread within and between hosts. Am J Pathol 168: 176–183

145 Karaca K, Swayne DE, Grosenbaugh D, Bublot M, Robles A, Spackman E, Nordgren R (2005) Immunogenicity of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats. Clin Diagn Lab Immunol 12: 1340–1342

146 Saito T, Lim W, Suzuki T, Suzuki Y, Kida H, Nishimura SI, Tashiro M (2002) Characterization of a human H9N2 influenza virus isolated in Hong Kong. Vaccine 20: 125–133

147 Rimmelzwaan GF, Kuiken T, van Amerongen G, Bestebroer TM, Fouchier RA, Osterhaus AD (2001) Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol 75: 6687–6691

148 Kuiken T, Rimmelzwaan GF, Van Amerongen G, Osterhaus AD (2003) Pathology of human influenza A (H5N1) virus infection in cynomolagus macaques (Macaca fascicularis). Vet Pathol 40: 304–310

149 Chen H, Li Y, Li Z, Shi J, Shinya K, Deng G, Qi Q, Tian G, Fan S, Zhao H et al (2006) Properties and dissemination of H5N1 viruses isolated during an influenza outbreak in migratory waterfowl in western China. J Virol 80: 5976–5983

150 Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara H, Hatta Y, Hyun Kim J, Halfmann P, Hatta M et al (2007) Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445: 319–323

151 Center for Biologics Evaluation and Research (CBER) (2007) Guidance for Industry. Clinical data needed to support the licensure of pandemic influenza vaccines. Food and Drug Administration

152 European Agency for the Evaluation of Medicinal Products (EMEA) (2004) Guideline on Dossier Structure and Content for Pandemic Influenza Vaccine Marketing Authorization Application

153 Federal Register 21 CFR Parts 314 & 610 (2002) New Drug and Biological
Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies are Not Ethical or Feasible

154 Iida T, Bang FB (1963) Infection of the upper respiratory tract of mice with influenza A virus. *Am J Hyg* 77: 169–176

155 Loosli CG (1948) The pathogenesis and pathology of experimental air-borne influenza virus A infections in mice. *J Infect Dis* 84: 153–168

156 O’Neill E, Krauss SL, Riberdy JM, Webster RG, Woodland DL (2000) Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. *J Gen Virol* 81: 2689–2696

157 Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G (2005) Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. *Vaccine* 23: 5751–5759

158 Smith H, Sweet C (1988) Lessons from human influenza from pathogenicity studies with ferrets. *Rev Infect Dis* 10: 56–75

159 Smith W, Stuart-Harris CH (1936) Influenza infection of man from the ferret. *Lancet* 2: 121–123